Preparation and characterization of diltiazem nanocapsules: Influence of various polymers

G Ashwini Kumar, Amit Bhat, Shoba Rani

Abstract


Nanocapsules are submicroscopic colloidal drug delivery system and are composed of an oily or an aqueous core surrounded by a thin polymeric membrane. Nanocapsules have recently generated lot of interest in the area of controlled release with availability of biocompatible and biodegradable polymers. Nanocapsules of diltiazem were prepared with an objective of achieving controlled release of the drug in order to reduce the frequency of administration of drug, to obtain more uniform plasma concentration, and to improve patient compliance. Diltiazem was chosen as the model drug, as it is widely used in the treatment of chronic conditions such as hypertension and angina which require prolonged therapy. Nanocapsules were prepared by the interfacial deposition technique by taking different concentrations of polymers and phospholipid mixture.
Five best formulations were selected based on the encapsulation efficiency. The morphology of nanocapsules was assessed by scanning electron microscope and they were found to be smooth, spherical, and discrete. The particles followed normal size distribution with particle size in the range of 20 to 380 nm. In vitro release studies indicated prolonged release for all polymers for 48 hours, with polycaprolactone as the best polymer releasing about 95 to 98%.The formulations were stable at 4°C but unstable at 25°C, and hence recommended for storage in refrigeration.Thus, it can be concluded that nanocapsules
are a useful technology for controlled release of diltiazem.


Full Text:

PDF

References


Pge.utexas.edu [homepage on the Internet]. Austin: The University

of Texas at Austin-College of Engineering, Petroleum and geosystems

engineering department resources. Available from URL:http://www.

pe.Utexas.edu/Dept/Academic/CoursesSP2001/TC 357/chapters/

nanotech.htm. [Last cited 10th April, 2004]

Khar RK, Vyas SP. Nanoparticles in targeted and controlled drug delivery

novel carrier systems. New Delhi: CBS publishers and distributors; 2002.

Hiremath SR, Hota A. Nanoparticles as drug delivery systems. Indian J

Pharm Sci 1999;61:69-75.

Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule

technology: a review. Crit Rev Ther Drug Carrier Syst 2002;19:99-134.

Whelan J. Nanocapsules for controlled drug delivery. Drug Discov

Today 2001;6:1183-84.

Klinke WP, Juneau M, Grace M, Kostuk WJ, Pflugfelder P, Maranda CR,

et al. Usefulness of sustained release diltiazem for stable angina

pectoris. Am J Cardiol 1989;64:1249-52.

CDI, clinically dermatology illustrated [monograph on CD-ROM].

Thomson Micromedex. Micromedex® Healthcare Series, 2nd ed. San

Diego: 2005.

Handbook of Pharmaceutical Excipients. Pharmaceutical Press; 1996.

Resomer ® Product brochure, Boehringer Ingelheim Pharma KG.

Germany.

Benzyl benzoate [computer program]. Chemicalland.com. Seoul (Korea). Indian Pharmacopeia.4th ed. New Delhi: Government of India. Ministry of health and family welfare; 1996.

Kamath BV, Shivaram K, Shah AC. Selective spectrophotometeric

determination of diltiazem HCl in tablets. J Pharm Biomed Analysis

:407-9.

Bindu R, Chandrasekaran AK. Colorimetric estimation of diltiazem in

pharmaceutical formulation. In drugs. 1994.

Kamath BV, Shivram K. Extractive spectrophotometric method for

the determination of diltiazem HCl in its dosage forms. In Drugs

;29:50-2.

Fessi H, Puisieux F, Devissaguet J, Ammoury N, Benita S. Nanocapsule

formation by interfacial polymer deposition following solvent

displacement. Int J Pharm 1989;55:1-4.




DOI: http://dx.doi.org/10.22377/ajp.v4i3.223

Refbacks

  • There are currently no refbacks.